Suzhou Hengrui Callisyn Biomedical

Suzhou Hengrui Callisyn Biomedical is a specialized biotechnology subsidiary of Jiangsu Hengrui Pharmaceuticals, one of China's largest pharmaceutical companies. The company focuses on the research and development of innovative oncology therapeutics, particularly leveraging advanced drug delivery systems and targeted therapies. Its portfolio includes a range of small molecule inhibitors and biologics aimed at addressing unmet needs in solid tumors and various cancers. By integrating the parent company's extensive R&D infrastructure with specialized biomedical technologies, Hengrui Callisyn plays a key role in advancing the group's clinical-stage pipeline in the global oncology market.